Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have earned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $21.25.

Several equities research analysts recently issued reports on VNDA shares. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 18th. TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Piper Jaffray Companies reiterated an “overweight” rating and set a $23.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rice Hall James & Associates LLC lifted its position in shares of Vanda Pharmaceuticals by 1.0% during the 2nd quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 279 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Vanda Pharmaceuticals by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 45,562 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 541 shares during the period. American International Group Inc. raised its stake in shares of Vanda Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares during the period. Strs Ohio raised its stake in shares of Vanda Pharmaceuticals by 4.6% during the 1st quarter. Strs Ohio now owns 49,600 shares of the biopharmaceutical company’s stock valued at $694,000 after purchasing an additional 2,200 shares during the period. Finally, California Public Employees Retirement System raised its stake in shares of Vanda Pharmaceuticals by 3.8% during the 2nd quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock valued at $971,000 after purchasing an additional 2,200 shares during the period. 86.49% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down 0.57% during midday trading on Friday, hitting $17.35. The stock had a trading volume of 267,070 shares. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.00. The stock’s market capitalization is $778.29 million. The stock’s 50-day moving average is $16.23 and its 200-day moving average is $15.05.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.01 earnings per share. On average, equities research analysts anticipate that Vanda Pharmaceuticals will post ($0.44) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of “Buy” from Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/09/vanda-pharmaceuticals-inc-vnda-receives-consensus-rating-of-buy-from-brokerages.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.